{
    "Trade/Device Name(s)": [
        "Alinity i STAT High Sensitivity Troponin-I"
    ],
    "Submitter Information": "Abbott Laboratories Diagnostics Division",
    "510(k) Number": "K230994",
    "Predicate Device Reference 510(k) Number(s)": [
        "K202525"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MMI"
    ],
    "Summary Letter Date": "April 6, 2023",
    "Summary Letter Received Date": "April 7, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine Phosphokinase/Creatine Kinase Or Isoenzymes Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cardiac"
    ],
    "Analyte(s)": [
        "Cardiac troponin I (cTnI)"
    ],
    "Specimen Type(s)": [
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Alinity i system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Alinity i STAT High Sensitivity Troponin-I assay for quantitative determination of cardiac troponin I in plasma using CMIA on Alinity i system",
    "Indications for Use Summary": "Aid in the diagnosis of myocardial infarction (MI) by quantitatively measuring cardiac troponin I in human plasma (lithium heparin) on the Alinity i system",
    "fda_folder": "Clinical Chemistry"
}